Poster: MPN-336: MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib vs Placebo and Ruxolitinib in JAKi Treatment-Naïve Myelofibrosis Patients

Publisher Website
Google Scholar
Abstract
No abstract available